Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17

Archive Search

10 results
12:00 AM, Jun 08, 2009  |  BC Week In Review | Clinical News  |  Clinical Status

Apricitabine: Phase III ongoing

An independent DSMB recommended continuation of Avexa's international Phase III trial evaluating apricitabine at the 800 …
based on 16-week data from 3 treatment arms comparing 800 or 1,200 mg of oral apricitabine
3TC ) in about 900 HIV patients with NRTI resistance. Avexa said the 2 apricitabine
12:00 AM, Mar 23, 2009  |  BC Week In Review | Clinical News  |  Clinical Results

Apricitabine: Additional Phase IIb data

AVX-201 trial in 51 patients showed that about 87% of 39 patients receiving 800 mg apricitabine
as needed had undetectable plasma HIV levels …
were no serious adverse events and no patients have withdrawn from the study due to apricitabine-related …
12:00 AM, Mar 17, 2008  |  BC Week In Review | Clinical News  |  Clinical Results

Apricitabine: Phase IIb data

CD4+ cell counts doubled between week 24 and week 48. There was no evidence of apricitabine
resistance or apricitabine-related serious adverse events. For the third phase of study, beginning at week 24 …
all patients were switched to 800 mg apricitabine twice daily. Data from the first (see BioCentury …
12:00 AM, Mar 03, 2008  |  BC Week In Review | Clinical News  |  Clinical Status

Apricitabine: Phase IIb/III ongoing

of a double-blind, international Phase IIb/III (AVX-301) trial comparing 800 and 1,200 mg of oral apricitabine
3TC ) given twice daily in 1,014 treatment-experienced HIV patients. Avexa has worldwide rights to apricitabine
U.K.). Avexa Ltd. (ASX:AVX), Richmond, Australia   Shire plc (LSE:SHP; NASDAQ:SHPGY), Basingstoke, U.K.   Product: Apricitabine
12:00 AM, Jan 07, 2008  |  BC Week In Review | Clinical News  |  Clinical Status

Apricitabine: Phase III started

Avexa began a double-blind, international Phase III trial to compare oral apricitabine given twice daily vs …
lamivudine ( 3TC ) in about 900 patients. Avexa has worldwide rights to apricitabine from Shire …
2006). Avexa Ltd. (ASX:AVX), Richmond, Australia   Shire plc (LSE:SHP; NASDAQ:SHPGY), Basingstoke, U.K.   Product: Apricitabine
12:00 AM, Jan 07, 2008  |  BC Week In Review | Clinical News  |  Clinical Status

Apricitabine: Phase III start

will begin a double-blind, international Phase III trial in about 900 patients to compare oral apricitabine
an NRTI from Gilead Sciences Inc. (GILD, Foster City, Calif.). Avexa has worldwide rights to apricitabine
2006). Avexa Ltd. (ASX:AVX), Richmond, Australia   Shire plc (LSE:SHP; NASDAQ:SHPGY), Basingstoke, U.K.   Product: Apricitabine
12:00 AM, Dec 10, 2007  |  BC Week In Review | Clinical News  |  Preclinical Results

Avexa, Shire preclinical data

In vitro, apricitabine had antiviral activity against HIV strains resistant to integrase inhibitors, including Isentress raltegravir …
from Merck & Co. Inc. (MRK, Whitehouse Station, N.J.). AVX has worldwide rights to apricitabine, a …
29). Avexa Ltd. (ASX:AVX), Richmond, Australia   Shire plc (LSE:SHP; SHPGY), Basingstoke, U.K.   Product: Apricitabine
12:00 AM, Aug 13, 2007  |  BC Week In Review | Clinical News  |  Clinical Status

Apricitabine: Phase III start

This year, AVX plans to start a double-blind, international Phase III trial of oral apricitabine given …
twice daily in 600-800 patients. AVX has worldwide rights to apricitabine from SHP (see BioCentury, Jan …
29). Avexa Ltd. (ASX:AVX), Richmond, Australia   Shire plc (LSE:SHP; SHPGY), Basingstoke, U.K.   Product: Apricitabine
12:00 AM, Mar 26, 2007  |  BC Week In Review | Clinical News  |  Clinical Results

Apricitabine: Phase IIb data

the double-blind Phase IIb AVX-201 trial in 47 treatment-experienced HIV patients with the M184V mutation, apricitabine
log10 (85%) vs. a reduction of …
log 10 (99.7%) after 21 days. Patients received either 600 or 800 mg of twice-daily apricitabine
12:00 AM, Aug 01, 2005  |  BC Week In Review | Clinical News  |  Clinical Status

SPD754: Phase IIb started

Ltd. (ASX:AVX), Richmond, Australia   Shire Pharmaceuticals Group plc (LSE:SHP; SHPGY), Basingstoke, U.K.   Product: SPD754
AVX754   Business: Infectious   Molecular target: NA   Description: Cytidine analog nucleoside reverse transcriptase inhibitor …